Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e215-22. doi: 10.1016/j.ijrobp.2011.02.023. Epub 2011 Apr 29.
The optimal management of oral cavity squamous cell carcinoma (OCSCC) typically involves surgical resection followed by adjuvant radiotherapy or chemoradiotherapy (CRT) in the setting of adverse pathologic features. Intensity-modulated radiation therapy (IMRT) is frequently used to treat oral cavity cancers, but published IMRT outcomes specific to this disease site are sparse. We report the Dana-Farber Cancer Institute experience with IMRT-based treatment for OCSCC.
Retrospective study of all patients treated at Dana-Farber Cancer Institute for OCSCC with adjuvant or definitive IMRT between August 2004 and December 2009. The American Joint Committee on Cancer disease stage criteria distribution of this cohort included 5 patients (12%) with stage I; 10 patients (24%) with stage II (n = 10, 24%); 14 patients (33%) with stage III (n = 14, 33%); and 13 patients (31%) with stage IV. The primary endpoint was overall survival (OS); secondary endpoints were locoregional control (LRC) and acute and chronic toxicity.
Forty-two patients with OCSCC were included, 30 of whom were initially treated with surgical resection. Twenty-three (77%) of 30 surgical patients treated with adjuvant IMRT also received concurrent chemotherapy, and 9 of 12 (75%) patients treated definitively without surgery were treated with CRT or induction chemotherapy and CRT. With a median follow-up of 2.1 years (interquartile range, 1.1-3.1 years) for all patients, the 2-year actuarial rates of OS and LRC following adjuvant IMRT were 85% and 91%, respectively, and the comparable results for definitive IMRT were 63% and 64% for OS and LRC, respectively. Only 1 patient developed symptomatic osteoradionecrosis, and among patients without evidence of disease, 35% experienced grade 2 to 3 late dysphagia, with only 1 patient who was continuously gastrostomy-dependent.
In this single-institution series, postoperative IMRT was associated with promising LRC, OS, and lower late toxicity rates, and chemoradiotherapy was a successful treatment for patients with high-risk disease. In contrast, outcomes of radiation-based treatment for patients with inoperable locally advanced disease were markedly less successful.
口腔鳞状细胞癌(OCSCC)的最佳治疗方法通常是在存在不良病理特征的情况下进行手术切除,然后辅助放疗或放化疗(CRT)。调强放疗(IMRT)常用于治疗口腔癌,但针对该疾病部位的已发表的 IMRT 结果却很少。我们报告了达纳-法伯癌症研究所(Dana-Farber Cancer Institute)使用基于 IMRT 的治疗口腔鳞癌的经验。
对 2004 年 8 月至 2009 年 12 月期间在达纳-法伯癌症研究所接受辅助或根治性 IMRT 治疗的所有口腔鳞癌患者进行回顾性研究。该队列的美国癌症联合委员会(American Joint Committee on Cancer)疾病分期标准分布包括 5 例(12%)Ⅰ期患者;10 例(24%)Ⅱ期(n = 10,24%)患者;14 例(33%)Ⅲ期(n = 14,33%)患者;和 13 例(31%)Ⅳ期患者。主要终点是总生存(OS);次要终点是局部区域控制(LRC)和急性及慢性毒性。
共纳入 42 例口腔鳞癌患者,其中 30 例最初接受手术治疗。30 例接受手术治疗的患者中有 23 例(77%)接受了辅助 IMRT 治疗,同时还接受了同期化疗,12 例未接受手术的患者中有 9 例(75%)接受了 CRT 或诱导化疗联合 CRT 治疗。所有患者的中位随访时间为 2.1 年(四分位距 1.1-3.1 年),辅助 IMRT 后的 2 年生存率和 LRC 分别为 85%和 91%,而根治性 IMRT 的结果分别为 63%和 64%。只有 1 例患者出现症状性放射性骨坏死,在无疾病证据的患者中,35%出现 2 至 3 级迟发性吞咽困难,只有 1 例患者持续依赖胃造口术。
在这项单机构研究中,术后 IMRT 与良好的 LRC、OS 和较低的晚期毒性发生率相关,而放化疗是高危疾病患者的成功治疗方法。相比之下,基于放疗的治疗方法对不能手术的局部晚期疾病患者的疗效明显较差。